Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 3×
“Tumors display wide variances in cell differentiation and phenotype, and these variances may include low sensitivity or resistance to chemotherapeutics and pro-apoptotic agents [14].”
BackgroundTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151 · cited 2×
“Albumin is a versatile protein with many beneficial pharmaceutical properties, such as, high water solubility, stability to pH changes and organic solvents, biodegradability/biocompatibility, lack of toxicity and immunogenicity, and ease of modification [31].”
BackgroundLee, E. S., Oh, K. T., Kim, D., Youn, Y. S., & Bae, Y. H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.08.006 · Cited by 446
Self-citationHabashy, H. O., Powe, D. G., Staka, C. M., Rakha, E. A., Ball, G., Green, A. R., Aleskandarany, M., Paish, E. C., Douglas Macmillan, R., Nicholson, R. I., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0345-x · Cited by 236 · cited 1×
“To surmount this problem, we sought to add another system, that is, transferrinreceptor-mediated endocytosis, because transferrin receptors are highly expressed in MCF-7 cells [39,40].”
Background
Cited by
Current trends and challenges in cancer management and therapy using designer nanomaterials
Navya, P. N., Kaphle, A., Srinivas, S. P., Bhargava, S. K., Rotello, V. M., & Daima, H. K. (2019) · Nano Convergence · doi:10.1186/s40580-019-0193-2 · Cited by 672
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Spada, A., Emami, J., Tuszynski, J. A., & Lavasanifar, A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00046 · Cited by 591
An, F.-F., & Zhang, X.-H. (2017) · Theranostics · doi:10.7150/thno.19365 · Cited by 436
Albumin nanostructures as advanced drug delivery systems
Karimi, M., Bahrami, S., Ravari, S. B., Zangabad, P. S., Mirshekari, H., Bozorgomid, M., Shahreza, S., Sori, M., & Hamblin, M. R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1193149 · Cited by 422
Chen, Q., Wang, X., Wang, C., Feng, L., Li, Y., & Liu, Z. (2015) · ACS Nano · doi:10.1021/acsnano.5b00640 · Cited by 341
Nanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 333
Onto better TRAILs for cancer treatment
de Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martinez-Lostao, L. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.174 · Cited by 304
Wang, Y., Wu, Y., Liu, Y., Shen, J., Lv, L., Li, L., Yang, L., Zeng, J., Wang, Y., Zhang, L. W., et al. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201601341 · Cited by 302
Jiang, T., Mo, R., Bellotti, A., Zhou, J., & Gu, Z. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201303222 · Cited by 298
Perspectives on the past, present, and future of cancer nanomedicine
Youn, Y. S., & Bae, Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.008 · Cited by 285
Self-citationNosrati, H., Sefidi, N., Sharafi, A., Danafar, H., & Kheiri Manjili, H. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.12.033 · Cited by 277
A simple improved desolvation method for the rapid preparation of albumin nanoparticles
Jahanban-Esfahlan, A., Dastmalchi, S., & Davaran, S. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.05.032 · Cited by 254
Chen, Q., Chen, J., Liang, C., Feng, L., Dong, Z., Song, X., Song, G., & Liu, Z. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.006 · Cited by 188
Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles
Souri, M., Soltani, M., Moradi Kashkooli, F., & Kiani Shahvandi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.024 · Cited by 178
Multifunctional LUV Liposomes Decorated for BBB and Amyloid Targeting. A. In Vitro Proof-of-Concept
Papadia, K., Markoutsa, E., Mourtas, S., Giannou, A. D., La Ferla, B., Nicotra, F., Salmona, M., Klepetsanis, P., Stathopoulos, G. T., & Antimisiaris, S. G. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.02.019 · Cited by 40
Metadata
- Authors
- Bae, S., Ma, K., Kim, T. H., Lee, E. S., Oh, K. T., Park, E.-S., Lee, K. C., & Youn, Y. S.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 33
- Issue
- 5
- Pages
- 1536-1546
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2042983239
- Cited by
- 236
- References
- 5
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.